| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB600-302SS | |||
| Azide and BSA Free | NBP2-80675 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB200-103SS | |||
| Azide and BSA Free | NBP2-80898 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB600-336SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB200-111SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB200-108SS | |||
| Azide and BSA Free | NBP2-80674 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB110-60011SS | |||
| Azide and BSA Free | NBP2-81012 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Azide and BSA Free | NBP2-33074 | |||
| IHC-Prediluted | NBP2-44976 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB100-2521SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP1-49644SS | |||
![Western Blot: c-Myc Antibody (9E10) [NB600-302] - CtIP is phosphorylated by CDKs at multiple sites. Myc-BRCA1 and/or HA-CtIP WT or indicated mutants were expressed in 293T cells and co-immunoprecipitation was performed. Image collected and cropped by CiteAb from the following publication (//doi.org/10.1371/journal.pgen.1003277) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/c-Myc-Antibody-9E10-Western-Blot-NB600-302-img0022.jpg "Western Blot: c-Myc Antibody (9E10) [NB600-302] - CtIP is phosphorylated by CDKs at multiple sites. Myc-BRCA1 and/or HA-CtIP WT or indicated mutants were expressed in 293T cells and co-immunoprecipitation was performed. Image collected and cropped by CiteAb from the following publication (//doi.org/10.1371/journal.pgen.1003277) licensed under a CC-BY license.")
![Immunohistochemistry-Paraffin: c-Myc Antibody (9E10) [NB600-302] - c-Myc was detected in immersion fixed paraffin-embedded sections of human breast cancer using anti-human mouse monoclonal antibody (Catalog # NB600-302, clone 9E10) at 1:50 dilution overnight at 4 C. Tissue was stained using the VisuCyte anti-mouse HRP polymer detection reagent (Catalog # VC001) with DAB chromogen (brown) and counterstained with hematoxylin (blue). Images may not be copied, printed or otherwise disseminated without express written permission of Novus Biologicals a bio-techne brand.](http://images.novusbio.com/fullsize/c-Myc-Antibody-9E10-Immunohistochemistry-Paraffin-NB600-302-img0009.jpg)
![Simple Western: c-Myc Antibody (9E10) [NB600-302] - Simple Western lane view shows a specific band for c-Myc in 0.5 mg/ml of Jurkat lysate. This experiment as performed under reducing conditions using the 12-230 kDa separation system.](http://images.novusbio.com/fullsize/c-Myc-Antibody-9E10-Simple-Western-NB600-302-img0006.jpg)
![Western Blot: c-Myc Antibody (9E10) - BSA Free [NB600-302] - Western blotting analysis of unsorted (W) and sorted ROSl degrees w(L) and ROShigh(H) cells. Data shown are representative of at least two independent experiments.DyLight 650 conjugated version of this antibody used (NB600-302C). Image collected and cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/25857523/) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/c-Myc-Antibody-9E10-BSA-Free-Western-Blot-NB600-302-img0026.jpg)
![Immunocytochemistry/Immunofluorescence: c-Myc Antibody (9E10) [NB600-302] - HeLa cells were fixed for 10 minutes using 10% formalin and then permeabilized for 5 minutes using 1X TBS + 0.5% Triton-X100. The cells were incubated with anti-c-Myc (9E10) at 10 ug/ml overnight at 4C and detected with an anti-mouse Dylight 488 (Green) at a 1:500 dilution. Actin was detected with Phalloidin 568 (Red) at a 1:200 dilution. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 40X objective.](http://images.novusbio.com/fullsize/c-Myc-Antibody-9E10-Immunocytochemistry-Immunofluorescence-NB600-302-img0011.jpg)
![Flow (Intracellular): c-Myc Antibody (9E10) [NB600-302] - An intracellular stain was performed on U-937 cells with c-Myc Antibody (9E10) NB600-302PE (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 5 ug/mL for 30 minutes at room temperature. Both antibodies were conjugated to Phycoerythrin.. Using the PE format of this antibody.](http://images.novusbio.com/fullsize/c-Myc-Antibody-9E10-Flow-Intracellular-NB600-302-img0024.jpg)
![Western Blot: c-Myc Antibody (9E10) [NB600-302] - Analysis of c-myc in Jurkat cell lysates using NB600-302.](http://images.novusbio.com/fullsize/c-Myc-Antibody-9E10-Western-Blot-NB600-302-img0005.jpg)
![Western Blot: c-Myc Antibody (9E10) [NB600-302] - Flow cytometric analysis of ROS and the mitochondrial status. Western blotting analysis of unsorted (W) and sorted P1 and P2 cells. Data shown are representative of at least two independent experiments. Image collected and cropped by CiteAb from the following publication (www.nature.com/articles/ncomms7750) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/c-Myc-Antibody-9E10-Western-Blot-NB600-302-img0025.jpg)
![Flow Cytometry: c-Myc Antibody (9E10) [NB600-302] - An intracellular stain was performed on U-937 cells with c-Myc Antibody (9E10) NB600-302AF488 (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 10 ug/mL for 30 minutes at room temperature. Both antibodies were conjugated to Alexa Fluor 488.](http://images.novusbio.com/fullsize/c-Myc-Antibody-9E10-Flow-Cytometry-NB600-302-img0014.jpg)
![Flow Cytometry: c-Myc Antibody (9E10) [NB600-302] - An intracellular stain was performed on Jurkat cells with c-Myc Antibody (9E10) NB600-302R (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 5 ug/mL for 30 minutes at room temperature. Both antibodies were conjugated to DyLight 550.](http://images.novusbio.com/fullsize/c-Myc-Antibody-9E10-Flow-Cytometry-NB600-302-img0019.jpg)
![Flow (Intracellular): c-Myc Antibody (9E10) [NB600-302] - An intracellular stain was performed on U-937 cells with c-Myc Antibody (9E10) NB600-302F (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 10 ug/mL for 30 minutes at room temperature. Both antibodies were conjugated to FITC.. Using the FITC format of this antibody.](http://images.novusbio.com/fullsize/c-Myc-Antibody-9E10-Flow-Intracellular-NB600-302-img0023.jpg)
![Western Blot: c-Myc Antibody (9E10) - BSA Free [NB600-302] - NLRP2 interacts with SCMC components TLE6, OOEP, FILIA & NLRP5.(A) NLRP2 was overexpressed with myc-tagged OOEP, TLE6, NLRP5 & FILIA in HEK293T cells for 48 hours, immunoprecipitated with anti-NLRP2 or IgG as negative control & immunoblotted with anti-myc. Top panel shows specificity of anti-NLRP2 IP & bottom panel shows that NLRP2 binds to OOEP, TLE6, FILIA & NLRP5. Uncropped, full length western blots have been provided in Supplementary Figure 5. (B) Whole-mount immunofluorescence co-staining with anti-NLRP2 (green) & DAPI (blue) for nuclear staining on Nlrp2+/+ oocytes & embryos at 2-, 4-,16-cell & morula stages revealed a predominantly SCMC-like localization for NLRP2. Scale bars represent 200 μm. (C) Co-staining with anti-TLE6 (green) & DAPI (blue) of paraffin-embedded oocyte sections reveals a typical cortical stain of TLE6 in oocytes of Nlrp2+/+ dams but a more intense & diffuse stain in oocytes of Nlrp2tm1a/tm1a dams. Scale bars represent 10 μm. Image collected & cropped by CiteAb from the following publication (//www.nature.com/articles/srep44667), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb600-302_mouse-monoclonal-c-myc-antibody-9e10-310202416163779.jpg)
![Western Blot: c-Myc Antibody [NB600-335] - Detection of c-myc-tagged Protein by Western Blot. Samples: 200, 100, or 50 ng of E. coli whole cell lysate expressing a multi-tag fusion protein. Antibodies: Affinity purified, goat anti-c-myc antibody NB600-335 at 0.04 ug/ml (1:25,000). Detection: Chemiluminescence with an exposure time of 30 seconds.](http://images.novusbio.com/fullsize/c-Myc-Antibody-Western-Blot-NB600-335-img0006.jpg "Western Blot: c-Myc Antibody [NB600-335] - Detection of c-myc-tagged Protein by Western Blot. Samples: 200, 100, or 50 ng of E. coli whole cell lysate expressing a multi-tag fusion protein. Antibodies: Affinity purified, goat anti-c-myc antibody NB600-335 at 0.04 ug/ml (1:25,000). Detection: Chemiluminescence with an exposure time of 30 seconds.")
![Immunocytochemistry/Immunofluorescence: c-Myc Antibody [NB600-335] - HeLa cells were fixed for 10 minutes using 10% formalin and then permeabilized for 5 minutes using 1X PBS + 0.5% Triton X-100. The cells were incubated with anti-c-Myc conjugated to Alexa Fluor 488 [NB600-335AF488] at 20 ug/mL for 1 hour at room temperature. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 40X objective. Image using the Alexa Fluor 488 format of this antibody.](http://images.novusbio.com/fullsize/c-Myc-Antibody-Immunocytochemistry-Immunofluorescence-NB600-335-img0007.jpg)
![Western Blot: c-Myc Antibody [NB600-335] - Analysis using the HRP conjugate of NB600-335. Detection of 200, 100, or 50 ng of E. coli whole cell lysate expressing a multi-tag fusion protein. Antibody used at 0.4 ug/mL (1:25,000).](http://images.novusbio.com/fullsize/c-Myc-Antibody-Western-Blot-NB600-335-img0005.jpg)
![Western Blot: p53 Antibody (PAb 240) [NB200-103] - Analysis of p53 in MCF7 and HeLa lystates. Image courtesy of anonymous customer product review.](http://images.novusbio.com/fullsize/p53-Antibody-PAb-240-Western-Blot-NB200-103-img0001.jpg "Western Blot: p53 Antibody (PAb 240) [NB200-103] - Analysis of p53 in MCF7 and HeLa lystates. Image courtesy of anonymous customer product review.")
![Immunocytochemistry/Immunofluorescence: p53 Antibody (PAb 240) [NB200-103] - PC12 cells were fixed in 4% paraformaldehyde for 10 minutes and permeabilized in 0.5% Triton X-100 in PBS for 5 minutes. The cells were incubated with anti-p53 Antibody (PAb 240) NB200-103 at 2 ug/ml overnight at 4C and detected with an anti-mouse Dylight 488 (Green) at a 1:1000 dilution for 60 minutes. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 40X objective.](http://images.novusbio.com/fullsize/p53-Antibody-PAb-240-Immunocytochemistry-Immunofluorescence-NB200-103-img0013.jpg)
![Immunohistochemistry-Paraffin: p53 Antibody (PAb 240) [NB200-103] - p53 was detected in immersion fixed paraffin-embedded sections of human prostate cancer using anti-human mouse monoclonal antibody (Catalog # NB200-103) at 1:200 dilution overnight at 4C. Tissue was stained using the VisuCyte anti-mouse HRP polymer detection reagent (Catalog # VC001) with DAB chromogen (brown) and counterstained with hematoxylin (blue). Images may not be copied, printed or otherwise disseminated without express written permission of Novus Biologicals a bio-techne brand.](http://images.novusbio.com/fullsize/p53-Antibody-PAb-240-Immunohistochemistry-Paraffin-NB200-103-img0005.jpg)
![Flow Cytometry: p53 Antibody (PAb 240) [NB200-103] - An intracellular stain was performed on HeLa cells with p53 Antibody [PAb 240] NB200-103 (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 1.0 ug/mL for 30 minutes at room temperature, followed by Mouse IgG (H+L) Cross-Adsorbed Secondary Antibody, Dylight 550 (35503, Thermo Fisher).](http://images.novusbio.com/fullsize/p53-Antibody-PAb-240-Flow-Cytometry-NB200-103-img0010.jpg)
![Immunocytochemistry/Immunofluorescence: p53 Antibody (PAb 240) [NB200-103] - HeLa cells were fixed for 10 minutes using 10% formalin and then permeabilized for 5 minutes using 1X TBS + 0.5% Triton X-100. The cells were incubated with anti-p53 (PAb 240) [NB200-103] at a 1:200 dilution overnight at 4C and detected with an anti-mouse DyLight 488 (Green) at a 1:500 dilution. Actin was detected with Phalloidin 568 (Red) at a 1:200 dilution. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 40X objective.](http://images.novusbio.com/fullsize/p53-Antibody-PAb-240-Immunocytochemistry-Immunofluorescence-NB200-103-img0004.jpg)
![Immunocytochemistry/Immunofluorescence: p53 Antibody (PAb 240) [NB200-103] - HeLa cells were fixed in 4% paraformaldehyde for 10 minutes and permeabilized in 0.5% Triton X-100 in PBS for 5 minutes. The cells were incubated with anti-p53 Antibody (PAb 240) NB200-103 at 2 ug/ml overnight at 4C and detected with an anti-mouse Dylight 488 (Green) at a 1:1000 dilution for 60 minutes. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 100X objective and digitally deconvolved.](http://images.novusbio.com/fullsize/p53-Antibody-PAb-240-Immunocytochemistry-Immunofluorescence-NB200-103-img0011.jpg)
![Immunocytochemistry/Immunofluorescence: p53 Antibody (PAb 240) [NB200-103] - Neuro2a cells were fixed in 4% paraformaldehyde for 10 minutes and permeabilized in 0.5% Triton X-100 in PBS for 5 minutes. The cells were incubated with anti-p53 Antibody (PAb 240) NB200-103 at 2 ug/ml overnight at 4C and detected with an anti-mouse Dylight 488 (Green) at a 1:1000 dilution for 60 minutes. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 100X objective and digitally deconvolved.](http://images.novusbio.com/fullsize/p53-Antibody-PAb-240-Immunocytochemistry-Immunofluorescence-NB200-103-img0012.jpg)
![Flow (Intracellular): p53 Antibody (PAb 240) [NB200-103] - An intracellular stain was performed on HeLa cells with p53 (PAb240) NB200-103 (blue) and a matched isotype control NBP2-27287 (orange). Cells were fixed with 4% PFA and then permeablized with 0.1% saponin. Cells were incubated in an antibody dilution of 2.5 ug/mL for 30 minutes at room temperature, followed by APC-conjugated anti-mouse IgG secondary antibody F0101B.](http://images.novusbio.com/fullsize/p53-Antibody-PAb-240-Flow-Intracellular-NB200-103-img0003.jpg)
![Flow Cytometry: p53 Antibody (PAb 240) [NB200-103] - An intracellular stain was performed on HeLa cells with p53 (PAb240) NB200-103AF647 (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeablized with 0.1% saponin. Cells were incubated in an antibody dilution of 2.5 ug/mL for 30 minutes at room temperature. Both antibodies were conjugated to Alexa Fluor 647.](http://images.novusbio.com/fullsize/p53-Antibody-PAb-240-Flow-Cytometry-NB200-103-img0006.jpg)
![Flow Cytometry: p53 Antibody (PAb 240) [NB200-103] - An intracellular stain was performed on A549 cells with p53 (PAb240) NB200-103AF488 (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeablized with 0.1% saponin. Cells were incubated in an antibody dilution of 10 ug/mL for 30 minutes at room temperature. Both antibodies were conjugated to Alexa Fluor 488.](http://images.novusbio.com/fullsize/p53-Antibody-PAb-240-Flow-Cytometry-NB200-103-img0007.jpg)
![Flow Cytometry: p53 Antibody (PAb 240) [NB200-103] - An intracellular stain was performed on MCF7 cells with p53 [PAb 240] Antibody NB200-103AF647 (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 2.5 ug/mL for 30 minutes at room temperature. Both antibodies were conjugated to Alexa Fluor 647.](http://images.novusbio.com/fullsize/p53-Antibody-PAb-240-Flow-Cytometry-NB200-103-img0008.jpg)
![Flow Cytometry: p53 Antibody (PAb 240) [NB200-103] - An intracellular stain was performed on Neuro2a cells with p53 Antibody [PAb 240] NB200-103 (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 1.0 ug/mL for 30 minutes at room temperature, followed by Mouse IgG (H+L) Cross-Adsorbed Secondary Antibody, Dylight 550 (35503, Thermo Fisher).](http://images.novusbio.com/fullsize/p53-Antibody-PAb-240-Flow-Cytometry-NB200-103-img0009.jpg)
![Immunocytochemistry/Immunofluorescence: c-Myc Antibody [NB600-336] - Staining of K-562, U266, Daudi and normal T cells with c-Myc antibody. ICC/IF image submitted by a verified customer review.](http://images.novusbio.com/fullsize/c-Myc-Antibody-Immunocytochemistry-Immunofluorescence-NB600-336-img0010.jpg "Immunocytochemistry/Immunofluorescence: c-Myc Antibody [NB600-336] - Staining of K-562, U266, Daudi and normal T cells with c-Myc antibody. ICC/IF image submitted by a verified customer review.")
![Western Blot: c-Myc Antibody [NB600-336] - Detection of c-Myc in HtrA2-Myc Transfectant lysates .](http://images.novusbio.com/fullsize/c-Myc-Antibody-Western-Blot-NB600-336-img0012.jpg)
![Western Blot: c-Myc Antibody [NB600-336] - Analysis of c-Myc on Jurkat whole cell extract using NB600-336.](http://images.novusbio.com/fullsize/c-Myc-Antibody-Western-Blot-NB600-336-img0004.jpg)
![Western Blot: c-Myc Antibody [NB600-336] - Lane 1: control HEK293 cell lysate. Lane 2: CMYC over-expression in HEK293 cell lysate. WB image submitted by a verified customer review.](http://images.novusbio.com/fullsize/c-Myc-Antibody-Western-Blot-NB600-336-img0014.jpg)
![Immunohistochemistry: c-Myc Antibody [NB600-336] - Analysis of c-Myc in mouse prostate using DAB with hematoxylin counterstain.](http://images.novusbio.com/fullsize/c-Myc-Antibody-Immunohistochemistry-NB600-336-img0002.jpg)
![Western Blot: c-Myc Antibody [NB600-336] - c-Myc in MOLT-4 cells. WB image submitted by a verified customer review.](http://images.novusbio.com/fullsize/c-Myc-Antibody-Western-Blot-NB600-336-img0006.jpg)
![Western Blot: c-Myc Antibody [NB600-336] - Analysis of whole cell lysate (WCL) of Jurkat cells using anti-cMyc antibody (NB600-336) at 1:1000 dilution. HRP conjugated goat anti-rabbit IgG (H+L) cross adsorbed secondary antibody was used with ECL substrate for the detection of c-Myc antibody bound to the blotted protein. This c-Myc antibody detected the c-Myc specific band at its expected position (48-50kDa). The signal below 10 kDa in this blot is potentially the degraded protein and we have not characterized this band.](http://images.novusbio.com/fullsize/c-Myc-Antibody-Western-Blot-NB600-336-img0013.jpg)
![Western Blot: c-Myc Antibody [NB600-336] - Analysis using the HRP conjugate of NB600-336. Detection of c-Myc in NIH/3T3 cell lysates (30ug and 45ug per lane) using anti-c-Myc antibody. WB image submitted by a verified customer review.](http://images.novusbio.com/fullsize/c-Myc-Antibody-Western-Blot-NB600-336-img0009.jpg)
![Immunocytochemistry/Immunofluorescence: c-Myc Antibody [NB600-336] - Detection of c-myc Tagged Plakoglobin by Immunofluorescence. Samples: Human microvascular endothelial cells expressing c-myc tagged plakoglobin following transient transfection.](http://images.novusbio.com/fullsize/c-Myc-Antibody-Immunocytochemistry-Immunofluorescence-NB600-336-img0005.jpg)
![Simple Western: c-Myc Antibody [NB600-336] - Lane view shows a specific band for c-Myc in 0.05 mg/ml of Jurkat lysate. This experiment was performed under reducing conditions using the 12-230 kDa separation system.](http://images.novusbio.com/fullsize/c-Myc-Antibody-Simple-Western-NB600-336-img0007.jpg)
![Western Blot: p14ARF/CDKN2A Antibody [NB200-111] - Inhibition of AKT decreases p53mut stability. T24 cells were transfected with non-targeting control, AKT1, or p14ARF siRNA. Cells were treated with NCS348884 (4 i1/4M), Nutlin3A (5 i1/4M) or DMSO as indicated. Whole cell lysates were probed with the indicated antibodies. Image collected and cropped by Citeab from the following publication (AKT regulates NPM dependent ARF localization and p53mut stability in tumors. Oncotarget (2014)) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/p14ARF-CDKN2A-Antibody-Western-Blot-NB200-111-img0012.jpg "<b>Genetic Strategies Validation. </b>Western Blot: p14ARF/CDKN2A Antibody [NB200-111] - Inhibition of AKT decreases p53mut stability. T24 cells were transfected with non-targeting control, AKT1, or p14ARF siRNA. Cells were treated with NCS348884 (4 i1/4M), Nutlin3A (5 i1/4M) or DMSO as indicated. Whole cell lysates were probed with the indicated antibodies. Image collected and cropped by Citeab from the following publication (AKT regulates NPM dependent ARF localization and p53mut stability in tumors. Oncotarget (2014)) licensed under a CC-BY license.")
![<b>Genetic Strategies Validation. </b>Immunohistochemistry: p14ARF/CDKN2A Antibody [NB200-111] - Inhibition of AKT modulates p53 stability in-vivo and synergizes with ionizing radiation to inhibit tumor growth( Sections of PSN1 xenografts treated with three consecutive doses of MK-2206 (60 mg/kg). Sections of PSN1 xenografts and in-vitro PSN1 cells fixed and stained with anti-NPM (red) and anti-p14ARF (green). Image collected and cropped by Citeab from the following publication (AKT regulates NPM dependent ARF localization and p53mut stability in tumors. Oncotarget (2014)) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/p14ARF-CDKN2A-Antibody-Immunocytochemistry-Immunofluorescence-NB200-111-img0011.jpg)
![Immunocytochemistry/Immunofluorescence: p14ARF/CDKN2A Antibody [NB200-111] - p14ARF antibody was tested in HeLa cells with Dylight 488 (green). Nuclei were counterstained with DAPI (blue). Tubulin was stained with alpha tubulin (red).](http://images.novusbio.com/fullsize/p14ARF-CDKN2A-Antibody-Immunocytochemistry-Immunofluorescence-NB200-111-img0006.jpg)
![<b>Biological Strategies Validation. </b>Western Blot: p14ARF/CDKN2A Antibody [NB200-111] - ARF expression levels in OCI/AML3 cells after proteasome treatment. This image was submitted via customer Review.](http://images.novusbio.com/fullsize/p14ARF-CDKN2A-Antibody-Western-Blot-NB200-111-img0009.jpg)
![Flow Cytometry: p14ARF/CDKN2A Antibody [NB200-111] - p14ARF antibody was tested at 1:400 in HeLa cells using an Alexa Fluor 488 secondary (shown in purple). M1 is defined by unstained cells.](http://images.novusbio.com/fullsize/p14ARF-CDKN2A-Antibody-Flow-Cytometry-NB200-111-img0007.jpg)
![Western Blot: p14ARF/CDKN2A Antibody [NB200-111] - Analysis of HeLa Whole Cell Lysate (NB800-PC1) using p14ARF antibody (lot C) employing ECL detection method.](http://images.novusbio.com/fullsize/p14ARF-CDKN2A-Antibody-Western-Blot-NB200-111-img0008.jpg)
![Immunohistochemistry-Frozen: p14ARF/CDKN2A Antibody [NB200-111] - Mouse brain section, hippocampal (10 um thickness). 3% PFA perfused. 1:1000 dilultion. Image from verified customer review. Image using the Biotin form of this antibody.](http://images.novusbio.com/fullsize/p14ARF-CDKN2A-Antibody-Immunohistochemistry-Frozen-NB200-111-img0010.jpg)
![Western Blot: p14ARF/CDKN2A Antibody - BSA Free [NB200-111] - Inhibition of AKT decreases p53mut stability(A) T24 cells & PSN1 cells were treated with MK-2206 (5 μM) or DMSO for 24 hrs. Cells were fixed & stained with DAPI & anti-mutant p53 (OP29 clone). (B) T24 cells were pre-treated with MK-2206 (5 μM) or DMSO for 24 hrs before the addition of fresh media containing cyclohexamide (100 μM) (CHX) in combination with MK-2206 (5 μM) or DMSO for the times indicated. Nuclear extracts were prepared from treated cells & blotted with the indicated antibodies. Quantification is relative to initiation of CHX treatment for both conditions *, MK-2206 is 40% of DMSO control but taken as 1.0 for relative assessment. (C) H1299 cells were transfected with HA-tagged-ubiquitin & mutant p53 (R175H or R248W) as indicated. Transfected cells were treated with DMSO, MK-2206 (5 μM) or Nutlin3A (5 μM) for 16hrs as indicated. p53 immunoprecipitates & whole cell lysates were probed with the indicated antibodies. (D) T24 cells were transfected with non-targeting control or p14ARF siRNA & treated with DMSO, MK-2206 (5 μM) or the NPM oligomerisation inhibitor NCS348884 (4 μM) (Qi et al., 2008) as indicated. (E) T24 cells were transfected with non-targeting control, AKT1, or p14ARF siRNA. Cells were treated with NCS348884 (4 μM), Nutlin3A (5 μM) or DMSO as indicated. Whole cell lysates were probed with the indicated antibodies. (F) KPC mice derived KRASG12D p53 Floxed (p53Fl), KRASG12D p53R172H ARF+/+ & KRASG12D p53R172H ARF−/− pancreatic tumor cells were treated with MK-2206 (1μM), Nutlin3A (5μM) or DMSO as indicated. Whole cell lysates were probed with the indicated antibodies. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/25071014), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb200-111_rabbit-polyclonal-p14arf-cdkn2a-antibody-310202416203719.jpg)
![Western Blot: p14ARF/CDKN2A Antibody - BSA Free [NB200-111] - Inhibition of AKT decreases p53mut stability(A) T24 cells & PSN1 cells were treated with MK-2206 (5 μM) or DMSO for 24 hrs. Cells were fixed & stained with DAPI & anti-mutant p53 (OP29 clone). (B) T24 cells were pre-treated with MK-2206 (5 μM) or DMSO for 24 hrs before the addition of fresh media containing cyclohexamide (100 μM) (CHX) in combination with MK-2206 (5 μM) or DMSO for the times indicated. Nuclear extracts were prepared from treated cells & blotted with the indicated antibodies. Quantification is relative to initiation of CHX treatment for both conditions *, MK-2206 is 40% of DMSO control but taken as 1.0 for relative assessment. (C) H1299 cells were transfected with HA-tagged-ubiquitin & mutant p53 (R175H or R248W) as indicated. Transfected cells were treated with DMSO, MK-2206 (5 μM) or Nutlin3A (5 μM) for 16hrs as indicated. p53 immunoprecipitates & whole cell lysates were probed with the indicated antibodies. (D) T24 cells were transfected with non-targeting control or p14ARF siRNA & treated with DMSO, MK-2206 (5 μM) or the NPM oligomerisation inhibitor NCS348884 (4 μM) (Qi et al., 2008) as indicated. (E) T24 cells were transfected with non-targeting control, AKT1, or p14ARF siRNA. Cells were treated with NCS348884 (4 μM), Nutlin3A (5 μM) or DMSO as indicated. Whole cell lysates were probed with the indicated antibodies. (F) KPC mice derived KRASG12D p53 Floxed (p53Fl), KRASG12D p53R172H ARF+/+ & KRASG12D p53R172H ARF−/− pancreatic tumor cells were treated with MK-2206 (1μM), Nutlin3A (5μM) or DMSO as indicated. Whole cell lysates were probed with the indicated antibodies. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/25071014), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb200-111_rabbit-polyclonal-p14arf-cdkn2a-antibody-310202416212372.jpg)
![Immunocytochemistry/ Immunofluorescence: p14ARF/CDKN2A Antibody - BSA Free [NB200-111] - Inhibition of AKT modulates p53 stability in-vivo & synergizes with ionizing radiation to inhibit tumor growth(A) PSN1 xenografts (PSN1 cells co-injected with LTC-14 stellate cells) established in the flank of athymic nude mice were treated with MK-2206 (60 mg/kg-320 mg/kg) as indicated or beta -cyclo-dextrin (1.5 mg/ml) carrier. Xenograft tumors were lysed & lysates probed by western blot with the indicated antibodies. (B-D) Sections of PSN1 xenografts treated with three consecutive doses of MK-2206 (60 mg/kg). (B) Sections of PSN1 xenografts & in-vitro PSN1 cells fixed & stained with anti-NPM (red) & anti-p14ARF (green). (C) PSN1 xenografts treated with MK-2206 or carrier were stained with DAPI, anti-p53 (DO1) or p53mut (OP29 clone) (D) PSN1 xenografts treated with MK-2206 (60 mg/kg) or carrier were stained by immunohistochemical methods with anti-pS473-AKT, anti-phospho-S48-NPM (pS48-NPM) or p53. (E) PSN1 xenografts established in the flank of athymic nude mice were injected subcutaneously with two alternate day doses of MK-2206 (60 mg/kg) or carrier. Mice were subsequently treated with a single dose of IR (6 Gy) & tumor volumes measured regularly with callipers. Dash lines indicate tumor growth differential at 250 mm3. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/25071014), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb200-111_rabbit-polyclonal-p14arf-cdkn2a-antibody-310202416203724.jpg)
![Western Blot: p14ARF/CDKN2A Antibody - BSA Free [NB200-111] - Inhibition of AKT decreases p53mut stability(A) T24 cells & PSN1 cells were treated with MK-2206 (5 μM) or DMSO for 24 hrs. Cells were fixed & stained with DAPI & anti-mutant p53 (OP29 clone). (B) T24 cells were pre-treated with MK-2206 (5 μM) or DMSO for 24 hrs before the addition of fresh media containing cyclohexamide (100 μM) (CHX) in combination with MK-2206 (5 μM) or DMSO for the times indicated. Nuclear extracts were prepared from treated cells & blotted with the indicated antibodies. Quantification is relative to initiation of CHX treatment for both conditions *, MK-2206 is 40% of DMSO control but taken as 1.0 for relative assessment. (C) H1299 cells were transfected with HA-tagged-ubiquitin & mutant p53 (R175H or R248W) as indicated. Transfected cells were treated with DMSO, MK-2206 (5 μM) or Nutlin3A (5 μM) for 16hrs as indicated. p53 immunoprecipitates & whole cell lysates were probed with the indicated antibodies. (D) T24 cells were transfected with non-targeting control or p14ARF siRNA & treated with DMSO, MK-2206 (5 μM) or the NPM oligomerisation inhibitor NCS348884 (4 μM) (Qi et al., 2008) as indicated. (E) T24 cells were transfected with non-targeting control, AKT1, or p14ARF siRNA. Cells were treated with NCS348884 (4 μM), Nutlin3A (5 μM) or DMSO as indicated. Whole cell lysates were probed with the indicated antibodies. (F) KPC mice derived KRASG12D p53 Floxed (p53Fl), KRASG12D p53R172H ARF+/+ & KRASG12D p53R172H ARF−/− pancreatic tumor cells were treated with MK-2206 (1μM), Nutlin3A (5μM) or DMSO as indicated. Whole cell lysates were probed with the indicated antibodies. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/25071014), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb200-111_rabbit-polyclonal-p14arf-cdkn2a-antibody-310202416205197.jpg)
![Western Blot: p14ARF/CDKN2A Antibody - BSA Free [NB200-111] - Inhibition of AKT promotes enhanced MDM2 activity via the increased association between NPM & p14ARF(A) Npm−/−, p53−/−double null MEF were infected with pBABE retrovirus empty vector & pBABE expressing FLAG-tagged-NPM-WT, NPM-S48A or S48E as indicated. Immunopurification of NPM was done by pulling down with the Flag tag (middle panel) followed by elution of complexes by the Flag peptide & subsequent immunopurification of endogenous MDM2 (lower panel). (B) Nuclear immunoprecipitates of MDM2 from T24 cells treated with MK-2206 (5 μM, 24 hrs). Immunoprecipitates & lysates were blotted with the indicated antibodies. (C) T24 cells were treated with MK-2206 (5 μM) as indicated. p14ARF was immunoprecipitated from whole cell lysates & nuclear extracts & the association with NPM & MDM2 determined by western blot. Immunoprecipitates & lysates were blotted with the indicated antibodies. (D) MDM2 & (E) p53 ubiquinitation assay in H1299 cells transfected with wild type p53, HA-tagged ubiquitin & treated for 16 hrs with DMSO, MK-2206 (5 μM) or Nutlin3A (5 μM) as indicated. Immunoprecipitates & whole cell lysates were probed with the indicated antibodies. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/25071014), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb200-111_rabbit-polyclonal-p14arf-cdkn2a-antibody-310202416212370.jpg)
![Western Blot: p14ARF/CDKN2A Antibody - BSA Free [NB200-111] - Inhibition of AKT promotes enhanced MDM2 activity via the increased association between NPM & p14ARF(A) Npm−/−, p53−/−double null MEF were infected with pBABE retrovirus empty vector & pBABE expressing FLAG-tagged-NPM-WT, NPM-S48A or S48E as indicated. Immunopurification of NPM was done by pulling down with the Flag tag (middle panel) followed by elution of complexes by the Flag peptide & subsequent immunopurification of endogenous MDM2 (lower panel). (B) Nuclear immunoprecipitates of MDM2 from T24 cells treated with MK-2206 (5 μM, 24 hrs). Immunoprecipitates & lysates were blotted with the indicated antibodies. (C) T24 cells were treated with MK-2206 (5 μM) as indicated. p14ARF was immunoprecipitated from whole cell lysates & nuclear extracts & the association with NPM & MDM2 determined by western blot. Immunoprecipitates & lysates were blotted with the indicated antibodies. (D) MDM2 & (E) p53 ubiquinitation assay in H1299 cells transfected with wild type p53, HA-tagged ubiquitin & treated for 16 hrs with DMSO, MK-2206 (5 μM) or Nutlin3A (5 μM) as indicated. Immunoprecipitates & whole cell lysates were probed with the indicated antibodies. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/25071014), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb200-111_rabbit-polyclonal-p14arf-cdkn2a-antibody-310202416205120.jpg)
![Western Blot: c-Myc Antibody (9E11) [NB200-108] - Expression of cancer proliferation markers and in high SVCT-2 expression cell lines. Western blot analysis of c-Myc and cyclin D1 in Sw620 and Sw480 cell lines after co-treatment with L-ascorbic acid and phloretin. beta-actin was used as a loading control. Image collected and cropped by CiteAb from the following publication (//www.nature.com/articles/s41598-018-29386-7), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/c-Myc-Antibody-9E11-Western-Blot-NB200-108-img0011.jpg "Western Blot: c-Myc Antibody (9E11) [NB200-108] - Expression of cancer proliferation markers and in high SVCT-2 expression cell lines. Western blot analysis of c-Myc and cyclin D1 in Sw620 and Sw480 cell lines after co-treatment with L-ascorbic acid and phloretin. beta-actin was used as a loading control. Image collected and cropped by CiteAb from the following publication (//www.nature.com/articles/s41598-018-29386-7), licensed under a CC-BY license.")
![Immunohistochemistry-Paraffin: c-Myc Antibody (9E11) [NB200-108] - c-Myc was detected in immersion fixed paraffin-embedded sections of human breast cancer using anti-human mouse monoclonal antibody (Catalog # NB200-108, clone 9E11) at 1:600 dilution overnight at 4C. Tissue was stained using the VisuCyte anti-mouse HRP polymer detection reagent (Catalog # VC001) with DAB chromogen (brown) and counterstained with hematoxylin (blue).Images may not be copied, printed or otherwise disseminated without express written permission of Novus Biologicals a bio-techne brand.](http://images.novusbio.com/fullsize/c-Myc-Antibody-9E11-Immunohistochemistry-Paraffin-NB200-108-img0007.jpg)
![Flow Cytometry: c-Myc Antibody (9E11) [NB200-108] - An intracellular stain was performed on U937 cells with c-Myc [9E11] Antibody NB200-108AF594 (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 2.5 ug/mL for 30 minutes at room temperature. Both antibodies were conjugated to Alexa Fluor 594.](http://images.novusbio.com/fullsize/c-Myc-Antibody-9E11-Flow-Cytometry-NB200-108-img0014.jpg)
![Western Blot: c-Myc Antibody (9E11) [NB200-108] - Whole cell protein from PC3 (lane 1), U-2 OS (lane 2) and mouse testis (lane 3) was separated on a 12% gel by SDS-PAGE, transferred to PVDF membrane and blocked in 5% non-fat milk in TBST. The membrane was probed with 2.0 ug/ml anti-c-Myc in 1% milk, and detected with an anti-mouse HRP secondary antibody using chemiluminescence.](http://images.novusbio.com/fullsize/c-Myc-Antibody-9E11-Western-Blot-NB200-108-img0006.jpg)
![Western Blot: c-Myc Antibody (9E11) [NB200-108] - Expression of cancer proliferation markers in low SVCT-2 expressing cell lines. Expression of c-Myc and cyclin D1 was analyzed by western blotting in HCT15 and DLD-1 cell lines after L-ascorbic acid treatment. beta-actin was used as a loading control. Image collected and cropped by CiteAb from the following publication (//www.nature.com/articles/s41598-018-29386-7), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/c-Myc-Antibody-9E11-Western-Blot-NB200-108-img0012.jpg)
![Western Blot: c-Myc Antibody (9E11) [NB200-108] - Expression of cancer proliferation markers and in high SVCT-2 expression cell lines. Western blot analysis of c-Myc and cyclin D1 in Sw620 and Sw480 cell lines after co-treatment with L-ascorbic acid and phloretin. beta-actin was used as a loading control. Image collected and cropped by CiteAb from the following publication (//www.nature.com/articles/s41598-018-29386-7), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/c-Myc-Antibody-9E11-Western-Blot-NB200-108-img0013.jpg)
![Flow (Intracellular): c-Myc Antibody (9E11) [NB200-108] - An intracellular stain was performed on U-937 cells with c-Myc Antibody (9E11) NB200-108AF647 (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 2.5 ug/mL for 30 minutes at room temperature. Both antibodies were conjugated to Alexa Fluor 647.](http://images.novusbio.com/fullsize/c-Myc-Antibody-9E11-Flow-Intracellular-NB200-108-img0008.jpg)
![Flow Cytometry: c-Myc Antibody (9E11) [NB200-108] - An intracellular stain was performed on U-937 cells with c-Myc Antibody (9E11) NB200-108PE (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 2.5 ug/mL for 30 minutes at room temperature. Both antibodies were conjugated to Phycoerthrin.](http://images.novusbio.com/fullsize/c-Myc-Antibody-9E11-Flow-Cytometry-NB200-108-img0009.jpg)
![Flow Cytometry: c-Myc Antibody (9E11) [NB200-108] - An intracellular stain was performed on U-937 cells with c-Myc Antibody [9E11] NB200-108 (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 1.0 ug/mL for 30 minutes at room temperature, followed by Mouse IgG (H+L) Cross-Adsorbed Secondary Antibody.](http://images.novusbio.com/fullsize/c-Myc-Antibody-9E11-Flow-Cytometry-NB200-108-img0010.jpg)
![Western Blot: WT1 Antibody (6F-H2) [NB110-60011] - Hypomethylation of the Intron 1 CpG island results in WT1 expression. RNA was isolated from K562 and U937 cells growing under atmospheric conditions (Normox) and from U937 cells growing in 1% O2 (Hypox) and was analyzed by RT-PCR using primers that span exon 5 of the WT1 mRNA. Ribosomal RNA 36B4 is used as a positive control, and molecular weight markers (MW) are shown. Image collected and cropped by CiteAb from the following publication (//dx.plos.org/10.1371/journal.pone.0119837), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/WT1-Antibody-6F-H2-Western-Blot-NB110-60011-img0007.jpg "Western Blot: WT1 Antibody (6F-H2) [NB110-60011] - Hypomethylation of the Intron 1 CpG island results in WT1 expression. RNA was isolated from K562 and U937 cells growing under atmospheric conditions (Normox) and from U937 cells growing in 1% O2 (Hypox) and was analyzed by RT-PCR using primers that span exon 5 of the WT1 mRNA. Ribosomal RNA 36B4 is used as a positive control, and molecular weight markers (MW) are shown. Image collected and cropped by CiteAb from the following publication (//dx.plos.org/10.1371/journal.pone.0119837), licensed under a CC-BY license.")
![Immunohistochemistry-Paraffin: WT1 Antibody (6F-H2) [NB110-60011] - Staining of human kidney glomerulus tissue. Heat mediated antigen retrieval was performed by heating in citrate buffer (pH 6) at 95C for 20 minutes. Image from verified customer review.](http://images.novusbio.com/fullsize/WT1-Antibody-6F-H2-Immunohistochemistry-Paraffin-NB110-60011-img0006.jpg)
![Western Blot: WT1 Antibody (6F-H2) [NB110-60011] - Whole cell protein from human K562, HEK293 and kidney tissue was separated on a 12% gel by SDS-PAGE, transferred to PVDF membrane and blocked in 5% non-fat milk in TBST. The membrane was probed with 2.0 ug/ml anti-WT1 in block buffer and detected with an anti-mouse HRP secondary antibody using chemiluminescence.](http://images.novusbio.com/fullsize/WT1-Antibody-6F-H2-Western-Blot-NB110-60011-img0005.jpg)
![Immunohistochemistry: WT1 Antibody (6F-H2) [NB110-60011] - Analysis of Wilms Tumor 1 in human renal cancer using DAB with hematoxylin counterstain.](http://images.novusbio.com/fullsize/WT1-Antibody-6F-H2-Immunohistochemistry-NB110-60011-img0003.jpg)
![Simple Western: WT1 Antibody (6F-H2) [NB110-60011] - Lane view shows a specific band for WT1 in 0.5 mg/ml of Hek293 lysate. This experiment was performed under reducing conditions using the 12-230 kDa separation system.](http://images.novusbio.com/fullsize/WT1-Antibody-6F-H2-Simple-Western-NB110-60011-img0004.jpg)
![Western Blot: WT1 Antibody (6F-H2) - BSA Free [NB110-60011] - Hypomethylation of Intron 1 CpG island results in WT1 expression. (C) Cell lysates from K562, U937, & HL60 cells treated with CoCl2, 5-azacytidine, or untreated controls analyzed by WB using an antibody against WT1. Histone H3 used as a loading control. Size of molecular weight markers is in kDa. Image collected & cropped by CiteAb from the following publication (//dx.plos.org/10.1371/journal.pone.0119837), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb110-60011_mouse-monoclonal-wt1-antibody-6f-h2-310202415304296.jpg)
![Western Blot: KRAS Antibody (3B10-2F2) [H00003845-M01] - Western blot analysis of KRAS expression in lysates from human lung cancer cell lines: H23, H358, A549, and H441. Image from verified customer review.](http://images.novusbio.com/fullsize/KRAS-Antibody-3B10-2F2-Western-Blot-H00003845-M01-img0004.jpg "Western Blot: KRAS Antibody (3B10-2F2) [H00003845-M01] - Western blot analysis of KRAS expression in lysates from human lung cancer cell lines: H23, H358, A549, and H441. Image from verified customer review.")
![Western Blot: KRAS Antibody (3B10-2F2) [H00003845-M01] - Western Blot analysis of KRAS expression in transfected 293T cell line by KRAS monoclonal antibody (M01), clone 3B10-2F2.Lane 1: KRAS transfected lysate(21 KDa).Lane 2: Non-transfected lysate.](http://images.novusbio.com/fullsize/KRAS-Antibody-3B10-2F2-Western-Blot-H00003845-M01-img0012.jpg)
![Immunocytochemistry/Immunofluorescence: KRAS Antibody (3B10-2F2) [H00003845-M01] - Analysis of monoclonal antibody to KRAS on HeLa cell. Antibody concentration 10 ug/ml.](http://images.novusbio.com/fullsize/KRAS-Antibody-3B10-2F2-Immunocytochemistry-Immunofluorescence-H00003845-M01-img0006.jpg)
![Western Blot: KRAS Antibody (3B10-2F2) [H00003845-M01] - KRAS monoclonal antibody (M01), clone 3B10-2F2 Analysis of KRAS expression in HeLa.](http://images.novusbio.com/fullsize/KRAS-Antibody-3B10-2F2-Western-Blot-H00003845-M01-img0008.jpg)
![Western Blot: KRAS Antibody (3B10-2F2) [H00003845-M01] - miRNA-768-3p specifically targets K-ras. Effect of miRNA inhibitors that were reduced by co-culture on the level of pan-RAS, phospho-B-Raf and CD44 and pan-Akt by western blotting. Also shown is the effect of different miRNA inhibitors on the level of K-ras in H520 cells by western blot. Cropped blots are shown and were run under the same experimental conditions. Image collected and cropped by CiteAb from the following publication (//www.nature.com/articles/srep02392), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/KRAS-Antibody-3B10-2F2-Western-Blot-H00003845-M01-img0011.jpg)
![ELISA: KRAS Antibody (3B10-2F2) [H00003845-M01] - Detection limit for recombinant GST tagged KRAS is approximately 1ng/ml as a capture antibody.](http://images.novusbio.com/fullsize/KRAS-Antibody-3B10-2F2-ELISA-H00003845-M01-img0010.jpg)
![Western Blot: p53 Antibody (BP53-12) [NBP2-29453] - Western Blot Analysis of human HeLa cell lysate using p53 Antibody (BP53-12).](http://images.novusbio.com/fullsize/p53-Antibody-BP53-12-Western-Blot-NBP2-29453-img0010.jpg)
![Immunohistochemistry-Paraffin: p53 Antibody (BP53-12) [NBP2-29453] - p53 was detected in immersion fixed paraffin-embedded sections of human breast cancer tissue using a 1 ug/mL mouse anti-p53 monoclonal (NBP2-29453, Novus Biologicals) for 1 hour at room temperature followed by the appropriate HRP polymer reagent, anti-mouse IgG VisUCyte HRP polymer (VC001). Tissue was stained using DAB (brown) and counterstained with hematoxylin (blue).](http://images.novusbio.com/fullsize/p53-Antibody-BP53-12-Immunohistochemistry-Paraffin-NBP2-29453-img0008.jpg)
![Western Blot: p53 Antibody (BP53-12) [NBP2-29453] - Analysis of p53 1) A431 2) MCF7 and 3) HEK293 lysate probed with p53 antibody at 1 ug/ml. goat anti-mouse Ig HRP secondary antibody and PicoTect ECL substrate solution were used for this test.](http://images.novusbio.com/fullsize/p53-Antibody-BP53-12-Western-Blot-NBP2-29453-img0001.jpg)
![Immunohistochemistry-Paraffin: p53 Antibody (BP53-12) [NBP2-29453] - Formalin-paraffin human colon carcinoma stained with p53 Ab (BP53-12).](http://images.novusbio.com/fullsize/p53-Antibody-BP53-12-Immunohistochemistry-Paraffin-NBP2-29453-img0003.jpg)
![Simple Western: p53 Antibody (BP53-12) [NBP2-29453] - Simple Western lane view shows a specific band for p53 in 0.2 mg/ml of MDA-MB-231 lysate. This experiment was performed under reducing conditions using the 12-230 kDa separation system.](http://images.novusbio.com/fullsize/p53-Antibody-BP53-12-Simple-Western-NBP2-29453-img0004.jpg)
![Simple Western: p53 Antibody (BP53-12) [NBP2-29453] - Electropherogram image of the corresponding Simple western lane view. p53 antibody was used at 10 ug/ml dilution on MDA-MB-231 lysate(s) respectively.](http://images.novusbio.com/fullsize/p53-Antibody-BP53-12-Simple-Western-NBP2-29453-img0005.jpg)
![Western Blot: p53 Antibody [NB200-171] - Whole cell lysate (5, 15 and 50 ug) from 293T cells prepared using NETN lysis buffer. Antibody: Affinity purified rabbit antiP53 antibody used for WB at0.1 ug/ml. Detection: Chemiluminescence with an exposure time of 30 seconds.](http://images.novusbio.com/fullsize/p53-Antibody-Western-Blot-NB200-171-img0076.jpg "Western Blot: p53 Antibody [NB200-171] - Whole cell lysate (5, 15 and 50 ug) from 293T cells prepared using NETN lysis buffer. Antibody: Affinity purified rabbit antiP53 antibody used for WB at0.1 ug/ml. Detection: Chemiluminescence with an exposure time of 30 seconds.")
![Immunohistochemistry-Paraffin: p53 Antibody [NB200-171] - FFPE section of human lung cancer Antibody: Affinity purified rabbit anti- p53 used at 1:5,000 (0.2ug/ml). Detection: DAB](http://images.novusbio.com/fullsize/p53-Antibody-Immunohistochemistry-Paraffin-NB200-171-img0075.jpg)
![Flow Cytometry: p53 Antibody [NB200-171] - p53 in Jurkat Cells, fixed in 1.5% PFA, and permeabilized in 90% Methanol. 1 million cells were stained with 1.5 ug anti-KLH IgG control or anti-p53 NB200-171 and secondary FITC-conjugated goat anti-rabbit (in a 150ul reaction). Black- anti-KLH control IgG; Red- anti-HDMX.](http://images.novusbio.com/fullsize/p53-Antibody-Flow-Cytometry-NB200-171-img0002.jpg)
![Chromatin Immunoprecipitation Sequencing: p53 Antibody [NB200-171] - Chromatin from MCF7 was immunoprecipitated with anti-p53 antibody and analyzed by DNA sequencing. The figure illustrates the peak distribution of p53 binding within a 250 Kb region of chromosome 6 as detected using anti-p53. ChIP-seq validation performed by Active Motif, Carlsbad, CA.](http://images.novusbio.com/fullsize/p53-Antibody-Chromatin-Immunoprecipitation-Sequencing-NB200-171-img0073.jpg)
![<b>Genetic Strategies Validation. </b>Western Blot: p53 Antibody [NB200-171] - Whole cell lysate (100 ug) from 293T cells that were treated with an siRNA for p53 (+) or mock treated (-). Antibody used at the indicated concentrations.](http://images.novusbio.com/fullsize/p53-Antibody-Western-Blot-NB200-171-img0003.jpg)
![Flow Cytometry: p53 Antibody [NB200-171] - Baseline p53 expression in human lymphocytes. Image from verified customer review.](http://images.novusbio.com/fullsize/p53-Antibody-Flow-Cytometry-NB200-171-img0004.jpg)
![<b>Independent Antibodies Validation. </b>Immunoprecipitation: p53 Antibody [NB200-171] - Detection of human P53 by western blot of immunoprecipitates. Samples: Whole cell lysate (1.0 mg per IP reaction; 20% of IP loaded) from HEK293T cells prepared using NETN lysis buffer. Antibodies: Affinity purified rabbit anti-P53 antibody NB200-171 used for IP at 3 ug per reaction. P53 was also immunoprecipitated by rabbit anti-P53 antibody NB100-2204. For blotting immunoprecipitated P53, NB200-171 was used at 1 ug/ml. Detection: Chemiluminescence with an exposure time of 30 seconds.](http://images.novusbio.com/fullsize/p53-Antibody-Immunoprecipitation-NB200-171-img0077.jpg)
![Western Blot: Speedy/Ringo Antibody [NB100-2521] - Spy1 protein levels are elevated in human breast cancers. TMAs containing cores from invasive ductal carcinoma (IvDC), infiltrated ductal carcinoma (IfDC), intraductal carcinoma (IDC) and invasive lobular carcinoma (ILC) as well as pair-matched normal (PM-N) or cancer-free patients (CF-N) were analyzed for Spy1 expression. The Spy1 signal intensity was normalized to nuclear stain (TOTO-3/PI) signal. Patient numbers are indicated below the sample (N). Breast normal and cancer cell lines were analyzed by western blot analysis. Actin was used as a loading control. One representative blot of 2. Image collected and cropped by Citeab from the following publication (The cyclin-like protein Spy1/RINGO promotes mammary transformation and is elevated in human breast cancer. BMC Cancer (2012)) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/Speedy-Ringo-Antibody-Western-Blot-NB100-2521-img0006.jpg "Western Blot: Speedy/Ringo Antibody [NB100-2521] - Spy1 protein levels are elevated in human breast cancers. TMAs containing cores from invasive ductal carcinoma (IvDC), infiltrated ductal carcinoma (IfDC), intraductal carcinoma (IDC) and invasive lobular carcinoma (ILC) as well as pair-matched normal (PM-N) or cancer-free patients (CF-N) were analyzed for Spy1 expression. The Spy1 signal intensity was normalized to nuclear stain (TOTO-3/PI) signal. Patient numbers are indicated below the sample (N). Breast normal and cancer cell lines were analyzed by western blot analysis. Actin was used as a loading control. One representative blot of 2. Image collected and cropped by Citeab from the following publication (The cyclin-like protein Spy1/RINGO promotes mammary transformation and is elevated in human breast cancer. BMC Cancer (2012)) licensed under a CC-BY license.")
![Western Blot: Speedy/Ringo Antibody [NB100-2521] - Spy1 stable protein induces anchorage independent growth. Representative foci after 14 day soft agar assay visualized using light microscopy. Ras-V12 is transfected as a positive control. n = 3. Total numbers of foci were counted over 3 separate plates using separate transfections for each experiment. n = 3. Error bars reflect SE between triplicate experiments. t test was performed. Western blot analysis of experiments performed. Quantified using densitometry followed by normalization for Actin levels. Image collected and cropped by Citeab from the following publication (The cyclin-like protein Spy1/RINGO promotes mammary transformation and is elevated in human breast cancer. BMC Cancer (2012)) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/Speedy-Ringo-Antibody-Western-Blot-NB100-2521-img0005.jpg)
![Immunohistochemistry-Paraffin: Speedy/Ringo Antibody [NB100-2521] - Speedy/Ringo was detected in immersion fixed paraffin-embedded sections of human testis using Rabbit Anti-Human Speedy/Ringo polyclonal Antibody (Catalog # NB100-2521) at 1:300 for 1 hour at room temperature followed by incubation with the Anti-Rabbit IgG VisUCyte™ HRP Polymer Antibody (Catalog # VC003). Tissue was stained using DAB (brown) and counterstained with hematoxylin (blue). Specific staining was localized to the nuclei of sperm cells.](http://images.novusbio.com/fullsize/Speedy-Ringo-Antibody-Immunohistochemistry-Paraffin-NB100-2521-img0004.jpg)
![Western Blot: Speedy/Ringo Antibody [NB100-2521] - Detection of Speedy/Ringo in mouse testis (2ug/ml).](http://images.novusbio.com/fullsize/Speedy-Ringo-Antibody-Western-Blot-NB100-2521-img0003.jpg)
![Western Blot: Speedy/Ringo Antibody [NB100-2521] - Elevated Spy1 levels prevent contact inhibition. (A) Representative views of focus formation assays in NIH3T3 cells transfected with Myc-Spy1-WT, Myc-Spy1-TST, positive control Ras-V12 or empty vector PCS3 control. n = 3 (B) Quantification of the number of colonies. Error bars reflect SE between triplicate experiments. t test was performed;** P ≤ 0.01. n = 3 (right panel) Western blot analysis of one representative lysate from A-B. Image collected & cropped by CiteAb from the following publication (//bmccancer.biomedcentral.com/articles/10.1186/1471-2407-12-45), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-2521_rabbit-polyclonal-speedy-ringo-antibody-31020241534341.jpg)
![Western Blot: Speedy/Ringo Antibody [NB100-2521] - Spy1 stable protein induces anchorage independent growth. (A) 293 cells were transfected with different concentrations of Myc-Spy1-WT, Myc-Spy1-TST or 30 μg of empty PCS3 vector control. Soft agar assay was carried out & plates photographed & quantified on day 14. Foci were averaged over 3 separate transfections for each experiment. n = 3 (B) Western blot analysis of one representative experiment; densitometry in lower panel. n = 3 (C) Representative foci after 14 day soft agar assay visualized using light microscopy. Ras-V12 is transfected as a positive control. n = 3. (D) Total numbers of foci were counted over 3 separate plates using separate transfections for each experiment. n = 3. Error bars reflect SE between triplicate experiments. t test was performed;** P ≤ 0.01. (E) Western blot analysis of experiments in Figure. 1C & D. Quantified using densitometry followed by normalization for Actin levels. (A-E) Error bars reflect SE between triplicate experiments. t test was performed;* P≤ 0.05, ** P ≤ 0.01, *** P ≤ 0.001. Image collected & cropped by CiteAb from the following publication (//bmccancer.biomedcentral.com/articles/10.1186/1471-2407-12-45), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-2521_rabbit-polyclonal-speedy-ringo-antibody-310202415541987.jpg)
![Immunocytochemistry/ Immunofluorescence: Speedy/Ringo Antibody [NB100-2521] - CDC2 associates with SPDY at ERES. (A-C) 0 h GV stage oocyte labeled for CDC2 (A, green), DNA (A, blue), & SPDY (B, red). Both CDC2 & SPDY localize to the same cortical domain (C). Note that the center of this oocyte is dented (the area that contains the arrow) causing the structure to appear in the middle of the oocyte, whereas it is located in the cortex. (D-F) 0 h GV stage oocyte stained for Cyclin B (D, green), DNA (D, blue), & P-GM130 (E, red). Cyclin B did not localize to the P-GM130-labeled cortical domain (F). (G-I) 0 h GV stage oocyte labeled for PSTAIR (G, green), DNA (G, blue), & P-GM130 (H, red). Spatial overlap of PSTAIR & phosphorylated GM130 staining (yellow) in a cortical domain is evident in the merged image (I). Images are Z-projections of 2 (A-C) or 3 (D-I) consecutive sections; scale bars represent 20 μm in C, F, & I, & 5 μm in C', F', & I'. Arrows indicate the region of the oocyte that is shown enlarged in the insets (A'-I'). Arrowheads denote the position of the GV. Image collected & cropped by CiteAb from the following publication (//bmcdevbiol.biomedcentral.com/articles/10.1186/1471-213X-9-8), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-2521_rabbit-polyclonal-speedy-ringo-antibody-31020241555219.jpg)
![Western Blot: Speedy/Ringo Antibody [NB100-2521] - Spy1 stable protein accelerates tumorigenesis in vivo.(A) Percentage of mice presenting with palpable tumors from 0-19 days post-transplant. Each data point represents 4 mice per indicated construct. The entire experiment was repeated three times using three independently derived overexpressing cell lines for each construct. Mann-Whitney Test was performed (p < 0.05). (A; lower blot) Western blots were conducted to measure the stability of Myc-Spy1-WT (left) & Myc-Spy1-TST (right) from representative time points. Empty vector control (Cntl) cell expression levels of Spy1 are seen in lane 1 of each blot. (B) Total tumor volume was calculated for both Spy1-HC11 (Spy1-WT) & Spy1-TST-HC11 (Spy1-TST) transplanted glands. Results were taken from 45 transplants using cells from 3 separate transfections. Error bars reflect SE between transplants from different transfections. Left hand panel reflects overall volume, right hand panel reflects volumes of tissues taken over a month post-transplant. Image collected & cropped by CiteAb from the following publication (//bmccancer.biomedcentral.com/articles/10.1186/1471-2407-12-45), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-2521_rabbit-polyclonal-speedy-ringo-antibody-31020241553735.jpg)
![Western Blot: Speedy/Ringo Antibody [NB100-2521] - Spy1 protein levels are elevated in human breast cancers.(A) TMAs containing cores from invasive ductal carcinoma (IvDC), infiltrated ductal carcinoma (IfDC), intraductal carcinoma (IDC) & invasive lobular carcinoma (ILC) as well as pair-matched normal (PM-N) or cancer-free patients (CF-N) were analyzed for Spy1 expression. The Spy1 signal intensity was normalized to nuclear stain (TOTO-3/PI) signal. Patient numbers are indicated below the sample (N). (B) Breast normal & cancer cell lines were analyzed by western blot analysis. Actin was used as a loading control. One representative blot of 2. (C) Western blot of 3 replicate infections of pLKO control or pLKO Spy1 in MDA-231 cells. Middle panel represents the densitometry values over 3 separate experiments. Where Spy1 is corrected for actin levels. Lower panel reflects cell counts at 4, 6, & 24 h post-infection. (All panels) Data shown is mean ± s.d. Student's t-test was performed * P < 0.05;**P < 0.01. (D) Knockdown effects on cell counts of MCF7 cells over 72 h after transfection with either pSUPER empty vector (siCntl) or pSUPER-Spy1 (siSpy1) over 3 separate transfections. Data shown is mean ± s.d. Image collected & cropped by CiteAb from the following publication (//bmccancer.biomedcentral.com/articles/10.1186/1471-2407-12-45), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-2521_rabbit-polyclonal-speedy-ringo-antibody-31020241555227.jpg)
![Western Blot: USP22 Antibody [NBP1-49644] - Western blot analysis of Usp22 in HeLa whole cell extracts.](http://images.novusbio.com/fullsize/USP22-Antibody-Western-Blot-NBP1-49644-img0001.jpg "Western Blot: USP22 Antibody [NBP1-49644] - Western blot analysis of Usp22 in HeLa whole cell extracts.")
![Western Blot: USP22 Antibody [NBP1-49644] - analysis of USP22 in HeLa whole cell lysate using anti-USP22 antibody. The primary antibody was used at a dilution of 1:500 and incubated overnight at 4C. Image from verified customer review.](http://images.novusbio.com/fullsize/USP22-Antibody-Western-Blot-NBP1-49644-img0002.jpg)
![Simple Western: USP22 Antibody [NBP1-49644] - Simple Western lane view shows a specific band for USP22 in 1.0 mg/ml of HeLa lysate. This experiment was performed under reducing conditions using the 12-230 kDa separation system.](http://images.novusbio.com/fullsize/USP22-Antibody-Simple-Western-NBP1-49644-img0003.jpg)
